

What follows is a listing of clinical trials that are currently recruiting participants in the Chapter's area. It contains an extremely brief overview of the clinical trial's purpose and inclusion/exclusion criteria. If interested, we urge you to find additional information about the study at www.clinicaltrials.gov using the ID number associated with each study, or by getting in touch with the contact person identified for the specific study. Also, to learn more about the clinical trial process, the risks involved, and your rights as a volunteer please visit our website or request a copy of our fact sheet on clinical trials.

Behavioral Studies:

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
Cognitive Behavior Therapy for Treating Anxiety in People With Dementia <i>National Institute of Mental Health (NIMH)</i> Jan. 2008 – Jun. 2010	60 years and older Diagnosis of Alzheimer's disease that is in the mild or moderate stage Significant anxiety English-speaking	Suicidal intent Current psychosis or bipolar disorder History of substance abuse within 1 month prior to study entry	Jessica Calleo, PhD 713-794-8521 jcalleo@bcm.tmc.edu Melinda A. Stanley, PhD 713-794-8841 mstanley@bcm.tmc.edu Trials are being conducted at both the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine in Houston.	NCT00596284
Partners in Dementia Care <i>Department of Veterans Affairs</i> <i>Benjamin Rose Institute</i> Dec. 2006 – May 2010	Diagnosis of dementia Veteran Live within the Alzheimer Association Chapter's service area	Live in long-term care facility	Brian Murry, MS (713) 794-8668 murry@bcm.tmc.edu Mark E Kunik, MD MPH (713) 794-8639 mkunik@bcm.tmc.edu Trials are being conducted at the Michael E. DeBakey Veterans Affairs Medical Center in Houston.	NCT00291161

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
Peaceful Mind: A Program for People with Anxiety and Memory Problems <i>Baylor College of Medicine</i> <i>Michael E. DeBakey Veteran Affairs Medical Center</i> <i>The National Institute of Mental Health</i>	50 years of age or older Have a problem with anxiety, worry, or “nerves” Are experiencing memory problems Are able to speak English Have a close friend or family member who would like to be involved in the program with you	No information provided.	Baylor College of Medicine Michael E. DeBakey Veterans Affairs Medical Center (713) 794-8521	N/A

Drug Studies:

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
<p>A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease</p> <p><i>Pfizer</i></p> <p><i>Alzheimer's Disease Cooperative Study (ADCS)</i></p> <p>Dec. 2007 – Mar. 2011</p>	<p>50 years of age or older</p> <p>Diagnosis of Alzheimer's disease</p> <p>Receiving acetyl cholinesterase inhibitors on a stable dose for at least 4 months prior to randomization</p>	<p>Evidence of any potential cause of dementia other than Alzheimer's disease</p> <p>Known history of familial AD or any evidence for early onset AD associated with genetic mutations</p> <p>Evidence or history of Type 1 or 2 diabetes mellitus</p> <p>History or symptoms of autoimmune disorders</p>	<p>Pfizer CT.gov Call Center 1-800-718-1021</p> <p>Trials are being conducted at the Pfizer Investigational Site in Houston.</p>	<p>NCT00566397</p>
<p>Safety & Efficacy Study Evaluating Dimebon in Patients with Mild to Moderate Alzheimer's Disease on Donepezil</p> <p><i>Medivation, Inc. & Pfizer</i></p> <p>March 2009 – December 2011</p>	<p>Mild-to-moderate Alzheimer's disease</p> <p>Probable AD (DSM-IV-TR)</p> <p>MMSE score between 12 and 24, inclusive</p> <p>Stable on donepezil for at least 6 months</p>	<p>Other causes of dementia</p> <p>Major structural brain disease</p> <p>Unstable medical condition or significant hepatic or renal disease</p>	<p>Anthony Golsorkhi, MD 415.829.4196</p> <p>Stewart Hallett, MBA 415.829.4113</p>	<p>NCT00829374</p>

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
Preliminary Efficacy & Safety Study of ST101 Plus Aricept in Alzheimer's Disease <i>Sonexa Therapeutics, Inc.</i> Feb. 2009 – Aug. 2010	Subjects must be receiving concurrent treatment with 10 mg/day of Aricept (donepezil). The dose shall have been stable for 3 months (90 days) prior to screening. Diagnostic evidence of Moderate to Moderately Severe Probable Alzheimer's disease CT or MRI results within the past 18 months that rule out dementia due to non-Alzheimer's etiology. A reliable and capable caregiver.	Subjects who reside in a skilled nursing facility Subjects with B12 or folate deficiency Subjects with chronic hepatic disease Subjects with a recent history of hematologic / oncologic disorders Subjects who have experienced a myocardial infarction within the past year	Barbra LaPlante 858-356-6250	NCT00842816

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) <i>Elan Pharmaceuticals</i> Dec. 2007 – Dec. 2010	Diagnosis of probable AD Age from 50 to less than 89 Mini-Mental Status Exam score of 16-26 inclusive MRI scan consistent with a diagnosis of AD Stable doses of medication (cholinesterase inhibitors & memantine allowed) Caregiver able to attend all clinic visits with patient	Significant neurological disease other than AD Major psychiatric disorder Significant systemic illness History of stroke, seizure, autoimmune disease, myocardial infarction within the last 2 years Smoking greater than 20 cigarettes a day Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications Prior treatment experimental immunotherapeutics or vaccines for AD Women of childbearing potential Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body	Study Coordinator 1-866-446-5463 Trials are being conducted at Baylor College of Medicine	NCT00574132

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
Effect of Testosterone Therapy in Men With Mild Alzheimer's Disease and Low Testosterone <i>Michael E. DeBakey Veterans Affairs Medical Center, Houston</i> <i>Solvay Pharmaceuticals</i> Apr. 2007 – Dec. 2009	65 years of age and older male Diagnosis of Alzheimer's disease Right-handed Sufficient English to perform cognitive testing Stable on concomitant medications for 1 month prior to starting study	Testosterone or other androgen treatment within the past 3 months History of <ul style="list-style-type: none"> - breast or prostate cancer - myocardial infarction - renal or hepatic disease - sleep apnea - non-AD neurological illness - major psychiatric illness - significant uncontrolled systemic illness - gonadal endocrine disorders Alcoholism or substance abuse within the past year	Robert S. Tan, MD 713-794-7382 Robert.Tan@med.va.gov Maurita Carrejo, MS 713-794-8766 Maurita.Carrejo@med.va.gov Trials are being conducted at the Michael E. DeBakey Veterans Affairs Medical Center in Houston.	www.clinicaltrials.gov NCT00392912

Official Study Title, Sponsor(s), and Duration of Study	Inclusion Criteria	Exclusion Criteria	Contact Information	www.clinicaltrials.gov ID number
<p>A Phase 3 Study to Evaluate the Safety & Tolerability of Dimebon Patients with Mild to Moderate Alzheimer's Disease</p> <p><i>Pfizer & Medivation, Inc.</i></p> <p>February 2009 – March 2010</p>	<p>Diagnosis of Alzheimer's disease</p> <p>MMSE 12-26 inclusive</p> <p>If on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.</p> <p>If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing in this study.</p>	<p>Have major structural brain disease (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, or a single lesion in a critical region [e.g., thalamus, hippocampus]).</p> <p>Have any major medical illness or unstable medical condition within six months of screening that may interfere with the patient's ability to comply with study procedures and abide by study restrictions.</p> <p>Have not been on a stable dose of anti-dementia therapy for at least 60 days prior to dosing or intend to start anti-dementia therapy during the double blind portion of the study.</p> <p>Reside in a nursing home or assisted care facility with need for 24-hour care and supervision.</p>	<p>Pfizer CT.gov Call Center 1-800-718-1021</p> <p>Trials are being conducted at the Pfizer Investigational Site in Houston.</p>	<p>NCT00838110</p>